Jae Kim, M.D. is Chief Medical Officer at Design Therapeutics. He has deep experience developing innovative therapies across multiple diseases and therapeutic modalities through all phases of drug development. Prior to joining Design, Dr. Kim was Chief Medical Officer of Avidity Biosciences. Prior to Avidity, he served as Clinical Research Head, Vice President of Clinical Development and Chair of the Clinical Trial Review Board at Alnylam Pharmaceuticals. Before Alnylam, he served in roles of increasing responsibility in global development at MyoKardia, Inc. and Amgen. He contributed substantially to the development and/or approvals of Givlaari® (givosiran), Amvuttra® (vutrisiran), Leqvio® (inclisiran), Camzyos® (mavacamten), Corlanor® (ivabradine), and Repatha® (evolocumab). Dr. Kim received his B.A. in Neurobiology Magna Cum Laude from Cornell University and his M.D. from Cornell University Medical College. He completed his post-doctoral fellowship in genetics at Harvard Medical School and his clinical training in cardiovascular disease at the Brigham and Women’s Hospital and Massachisetts General Hospital, and he served on the Faculty of Medicine at Harvard Medical School and the Brigham and Women’s Hospital before joining industry.